Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease

Abstract

This preliminary report suggests that the use of Bosentan in the treatment of PH in COPD is beneficial.

Effect of tiotropium on quality of life in COPD: a systematic review

“…[33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] Of the 24 publications that met the inclusion criteria for this systematic review (see Table 1), 16 compared tiotropium with placebo, [50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65] seven compared tiotropium with an active comparator, [66][67][68][69][70][71][72] and one compared tiotropium with both placebo and an active comparator. 73 The QoL outcomes reported in the 24 included publications were mostly SGRQ and/or TDI (Tables 2 and 3).…”

Disproportionate Pulmonary Hypertension in a Patient with Early-onset Pulmonary Emphysema Treated with Specific Drugs for Pulmonary Arterial Hypertension

“…Since these studies included patients with only mild to moderate pulmonary hypertension or exercise-induced pulmonary hypertension, it is important to note that the results may not apply to severe pulmonary hypertension in COPD. Some reports have shown improvement in functional status and hemodynamic parameters after bosentan therapy in COPD patients with severe pulmonary hypertension (12)(13)(14). Oxygenation and cardiac output were well maintained after bosentan therapy.…”

Pulmonary Hypertension in COPD

“…9 It was speculated that COPD patients with severe PH but only mild to moderate ventilatory impairment might benefit from vasoactive medication. 2 However, the reported effects of vasoactive drugs have been inconsistent [10][11][12][13] and reliable corroborating data are lacking.…”

“…3,4,7 The positive effect of the endothelin receptor antagonist bosentan on PH due to hypoxic PH and COPD was shown in animal models as well as in humans. [10][11][12] Stolz et al 13 concluded that bosentan failed to improve functional capacity in COPD patients without severe PH, but this cohort was not investigated by right heart catheterization, and the group treated with bosentan had a mean systolic pulmonary artery pressure of only 32 mm Hg.…”